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Abstract
Duration of initial disease response remains a strong prognostic factor in multiple myeloma (MM) 
particularly for upfront autologous hematopoietic cell transplant (AHCT) recipients. We 
hypothesized that new drug classes and combinations employed prior to AHCT as well as after 
post-AHCT relapse may have changed the natural history of MM in this population. We analyzed 
the Center for International Blood and Marrow Transplant Research database to track overall 
survival (OS) of MM patients receiving single AHCT within 12 months after diagnosis (N=3,256) 
and relapsing early post-AHCT (<24 months), and to identify factors predicting for early vs. late 
relapses (24–48 months post-AHCT). Over 3 periods (2001–2004, 2005–2008, 2009–2013), 
patient characteristics were balanced except for lower proportion of Stage III, higher likelihood of 
1 induction therapy with novel triplets and higher rates of planned post-AHCT maintenance over 
time. The proportion of patients relapsing early was stable over time at 35–38%. Factors reducing 
risk of early relapse included lower stage, chemosensitivity, transplant after 2008 and post-AHCT 
maintenance. Shorter post-relapse OS was associated with early relapse, IgA MM, Karnofsky <90, 
stage III, >1 line of induction and lack of maintenance. Post-AHCT early relapse remains a poor 
prognostic factor, even though outcomes have improved over time.
INTRODUCTION
Autologous hematopoietic cell transplantation (AHCT) continues to be an integral 
component of initial treatment strategy in eligible patients with multiple myeloma (MM).1–6 
Significant progress has been made in prolonging the duration of initial disease control 
through judicious combination of effective initial therapy, and AHCT with post-transplant 
consolidation and maintenance therapy of varying duration.7, 8 However, most patients 
eventually relapse and the duration of initial disease control appears to be one of the most 
important prognostic factors for survival in patients with MM, likely a reflection of the 
underlying high-risk disease biology that may not be always reflected accurately in the 
baseline laboratory and MM-relevant fluorescent in situ hybridization (FISH) findings.9–11 
Prior studies have shown that the time to progression after AHCT reliably predicts the 
overall survival from the time of relapse and in fact this has been commonly used as a metric 
for determining the potential benefit from a second AHCT used as salvage therapy.9, 12, 13 In 
a study of 432 patients transplanted at Mayo Clinic within 12 months of their diagnosis, 94 
patients (22%) had relapsed within 12 months of their transplant.12 Median overall survival 
(OS) from diagnosis was 23.9 months in the early relapse group compared to 82.2 months in 
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the late relapse group. Among the 265 patients who had disease progression after transplant, 
median overall survival from relapse was only 7.8 months for the early relapse group 
compared to 39.6 months for the late relapse group. Most of the available data reflect prior 
treatment approaches and the improvements in therapy over the past decade including the 
use of new drug classes and routine incorporation of post AHCT maintenance is likely to 
have altered these estimates. Finally, the risk factors associated with early treatment failure 
following AHCT as well as those associated with inferior outcomes post-relapse are not well 
understood in the context of modern therapies, and this knowledge will allow us to better 
predict risk and design clinical trials to improve outcomes.
We undertook the current study to specifically address how these clinical scenarios and their 
implications have changed during the recent decade, given the dramatic change in treatments 
and consequent improvement in OS of patients with MM. Specifically, we wanted to 
determine if risk of early relapse after AHCT has changed, if OS after early relapse has 
improved, the factors predicting early and late relapses after AHCT, and to compare post-
relapse survival among patients suffering an early relapse (<24 months from transplant) and 
those with more durable disease control. We used the Center for International Blood and 
Marrow Transplant Research (CIBMTR) database to conduct this analysis.
PATIENTS AND METHODS
Data Source
The CIBMTR is a prospectively maintained transplant database that captures transplant data 
from over 500 transplant centers worldwide. Data are submitted to a statistical center at the 
Medical College of Wisconsin in Milwaukee. Participating centers are required to report all 
transplants consecutively; patients are followed longitudinally and compliance is monitored 
by onsite audits. Computerized checks for discrepancies, physicians’ review of submitted 
data, and onsite audits of participating centers ensure data quality. Observational studies 
conducted by the CIBMTR are performed in compliance with all applicable federal 
regulations pertaining to the protection of human research participants. Protected Health 
Information used in the performance of such research is collected and maintained in 
CIBMTR’s capacity as a Public Health Authority under the HIPAA Privacy Rule.
The specific objectives for the study were to determine if OS has improved between January 
2001 and December 2013 among patients relapsing early (<24 months) after an AHCT, to 
determine factors predicting early and late relapses (24–48 months) after AHCT and to 
compare post-relapse survival among early relapse (<24 months from AHCT) and late 
relapse (24–48 months from AHCT).
Patient Selection
Patients who underwent first AHCT for MM in the United States or Canada from 2001–
2013 and reported to CIBMTR were considered for the current study. Patients undergoing 
late AHCT (>12 months from diagnosis), those undergoing tandem transplants, those 
receiving non-melphalan based conditioning, and those with unknown induction treatment 
agents were excluded. Patients were required to have at least 100 days follow up or death 
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prior to 100 days after AHCT and should have consented to research participation; those 
with unknown relapse status were excluded. The disposition of patients who were 
considered for inclusion is detailed in supplementary table 1.
Endpoints
The endpoints of interest included disease response, progression-free survival (PFS), and OS 
after transplant. Disease response was assessed using the International Myeloma Working 
Group (IMWG) consensus criteria.14 PFS was defined as time without progressive disease 
with patients alive and without progression/relapse censored at last follow-up. OS was 
defined as time from diagnosis or time of relapse after AHCT till death from any cause with 
censoring of surviving patients at last follow-up.
Statistical Methods
We examined the post-transplant OS in the entire cohort from diagnosis of myeloma, and 
OS from post-AHCT relapse in the group of patients with a documented relapse occurring 
within 24 months of AHCT comparing it to those with a relapse after 24 months or none at 
the time of last follow up. Univariate analysis was conducted to compare post-AHCT OS 
among the early relapse group over time. Patients were divided in 3 groups based on year of 
transplant, 2001–2004, 2005–2008 and 2009–2013. Two separate multivariate analyses were 
conducted: 1) Time to relapse from transplant was analyzed to identify factors associated 
with early relapse and relapse after 24 months. We fitted a left-truncation model where 
patients who relapsed after 24 months, their relapse time was truncated at 24 months. 
Factors that were studied included age, gender, race, Karnofsky Performance Score (KPS) at 
transplant, MM subtype (IgG, IgA, light chain, non-secretory, others), serum creatinine at 
diagnosis, stage at diagnosis (International Staging System or Durie Salmon Stage III versus 
I/II), lines of pre-transplant chemotherapy, novel triplet versus novel doublet versus non-
novel induction, melphalan conditioning dose, chemosensitivity, disease status at transplant, 
time from diagnosis to transplant, year of transplant, planned post-transplant therapy; 2) 
Post-relapse OS- this analysis which was conducted on all relapsed patients and included 
early versus late relapse in addition to all the aforementioned characteristics in the 
multivariate model.
RESULTS
The study included 3256 patients who underwent AHCT within 12 months of diagnosis and 
had data reported to the CIBMTR. The baseline characteristics are as shown in Table 1. The 
study cohort was divided into three groups based on the year of AHCT: 2001–2004 (n=896), 
2005–2008 (n=1401) and 2009–2013 (n=959). Patients in the most recent group were more 
likely to have received induction therapy with bortezomib, lenalidomide and dexamethasone, 
compared to the previous years and were more likely to come to transplant with a single line 
of prior therapy, reflecting the improved efficacy of current regimens. A higher proportion of 
patients received their transplant within 6 months from diagnosis in the most recent cohort. 
The median follow up from AHCT of the survivors in the three groups were 120, 86 and 39 
months respectively.
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Time of relapse and post-transplant outcomes
At the time of analysis, 17%, 20% and 46% of patients were alive without disease 
progression in the 2001–2004, 2005–2008, and 2009–2013 groups, respectively (Table 2). A 
higher proportion of patients in the most recent period had intent for planned post-AHCT 
consolidation and/or maintenance (72%) compared with 23% for the middle group and 6% 
for the earliest group. Median follow-up of survivors was 120 (3–170) months for 2001–
2004, 86 (3–129) months for 2005–2008 and 39 (3–82) months for 2009–2013 groups. The 
median PFS from AHCT for the 2001–2004, 2005–2008, and 2009 to 2013 groups was 31.2, 
29.9 and 30.4 months, respectively (Figure 1A). The median OS for the three groups were 
65.5, 79.5 and 88.8 months (p<0.001), respectively, suggesting improving survival over the 
time period. (Figure 1B) A similar proportion of patients had relapsed within 12 and 24 
months of AHCT during the three time periods (Table 2). Overall, 38%, 38% and 35% of 
patients had relapsed within 24 months of AHCT in the three groups respectively (Figure 
1C).
We initially examined the impact of early post-AHCT relapse on OS of patients and how it 
has changed in the recent years. The OS from diagnosis was 44.7 months (95% CI: 42.5–
48.2) for those relapsing within 24 months of AHCT compared with 113.7 months (95% CI:
108.2–121.7) for those who had not relapsed within 24 months, reflecting the poor disease 
biology associated with early relapse (Figure 2A). Among those relapsing within 24 months, 
the median OS from diagnosis was 38.1, 48.1 and 48.3 for 2001–2004, 2005–2008, and 
2009–2013 groups, respectively. For the remaining patients, the median OS from diagnosis 
was 102, 115.5 and 97.8 for the three time periods, respectively (p-value NS).
Post-relapse outcomes
We evaluated the survival outcomes from relapse, comparing the outcomes of those 
relapsing within 24 months of AHCT and those relapsing beyond 24 months from AHCT or 
have not relapsed at last follow up. The baseline characteristics and the transplant related 
characteristics of these three groups of patients are as shown in Table 3. On multivariate, 
factors influencing early relapse included advanced MM stage [Hazard Ratio, (HR) 1.2; 
95%CI: 1.0–1.3; p=0.02], chemo sensitivity (HR 0.8; 95%CI: 0.7–0.9, p=0.007), transplant 
after 2008 (HR 0.8; 95%CI: 0.7–0.98; p=0.02), and post-AHCT maintenance with novel 
agent (HR 0.8; 95%CI: 0.7–1.0, p=0.02) (Table 4).
The median OS from the time of relapse was significantly inferior for the early relapse 
group compared with the late relapse groups; P<0.001 (Figure 2B, Table 5a). Next, we 
observed that while post-relapse survival of both early and late relapse were improved in the 
2005–2013 period compared to 2001–2004, but improvements seemed greater for the late 
relapse group than for the early relapse group by year of transplant (Figure 2C). We then 
specifically examined the survival trends among the early relapse patients. Compared to 
patients transplanted in 2001–2004, patients with early relapse in the two later groups had 
improved OS from relapse (Figure 2D). The survival estimates over time for this group of 
patients are shown in Table 5b. We also examined the OS from relapse based on disease 
relapse before or after 2005. The median OS from relapse for those relapsing before 2005 
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was 16.4 months compared with 24.7 months for those relapsing after 2005; P <0.001. The 
survival estimates over time for this group of patients are shown in Table 5c.
We subsequently performed multivariate analysis to examine factors predicting for post-
relapse OS among patients relapsing early or late after AHCT. Risk factors for post-relapse 
OS on multivariate analysis included early relapse (HR 1.4; 95%CI: 1.3–1.6, p<0.0001), 
Karnofsky <90 (HR 1.2; 95%CI: 1.1–1.4; p=0.007), stage III myeloma (HR 1.3; 95%CI: 
1.1–1.4, p<0.0001), 2+ lines of chemotherapy (HR 1.2; 95%CI: 1.1–1.4, p=0.005), novel 
agent maintenance post-AHCT (HR 0.7; 95%CI: 0.6–0.9, p<0.0001), and IgA myeloma (HR 
1.3; 95%CI: 1.1–1.5; p=0.0006) (Table 6).
DISCUSSION
As the outcomes for MM patients continue to improve, disease heterogeneity has become 
increasingly evident, with nearly a quarter of patients continuing to have median overall 
survival of 2–3 years.15–20 These ‘high-risk’ patients are typically characterized by the 
presence of one or more cytogenetic abnormalities, but these abnormalities do not always 
account for the poor outcomes seen in some patients. Over the years, it has become apparent 
that patients with a short duration of response, particularly those relapsing early after AHCT, 
have a poor outcome, defining a functional high risk group of patients.9, 10, 12 Even in the 
current era with major improvements in the treatment approaches, especially more uniform 
application of highly effective regimens incorporating proteasome inhibitors and 
immunomodulatory drugs, AHCT continues to play a major role in the treatment of 
myeloma.2, 6, 7, 21 It is considered a standard component of the initial treatment approach for 
patients who can undergo this procedure. Much has changed in the context of transplant with 
better induction therapy, and uniform incorporation of post-transplant approaches such as 
consolidation and maintenance.4, 22–29 This study was undertaken to examine the clinical 
factors predicting early relapse in the face of these improvements in initial therapy and if the 
post relapse outcomes have improved with the increasing availability of novel classes of 
agents.
Examination of the baseline characteristics of the patients included in this study gives 
valuable information regarding the changing landscape of transplant utilization in North 
America, in the context of which the current results should be interpreted.2 The demographic 
characteristics of the patients going to transplant within 12 months of diagnosis has 
remained consistent over the study period. It is interesting to note a trend towards decreasing 
proportion of patients with International Staging System (ISS) stage 3 in the recent years, 
and may reflect an overall shift towards earlier treatment intervention among patients, a fact 
to be considered when interpreting the results.8 The type of induction regimens utilized pre-
AHCT shows a significant shift towards use of proteasome inhibitor/immunomodulatory 
drug combinations such as VRD, which was used in nearly half of the patients in the recent 
group. The increased use of this regimen is consistent with the current recommendations 
based on results from the phase 3 trial of this regimen.30, 31 The impact of this shift in 
induction regimen likely explains the increasing proportion of patients coming into 
transplant with just one line of initial therapy in the most recent cohort, and with chemo 
sensitive disease. The quicker response seen with the newer regimens also likely explains the 
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higher proportion of patients receiving transplant within 6 months of diagnosis in the most 
recent group. Finally, as expected a significantly higher proportion of patients were reported 
to have planned post-AHCT therapy in the form of maintenance with lenalidomide or 
bortezomib.
One of the striking findings of the current study is the lack of a substantial decrease in the 
proportion of patients who are relapsing within 24 months after AHCT; 38%, 38% and 35% 
during the three consecutive periods. Given that patients are likely to be going into 
transplant with more chemo sensitive disease, likely a deeper response and higher proportion 
with planned post AHCT therapy, the lack of improvement in this aspect of disease is 
intriguing as well as concerning. One potential explanation is that patients with genetically 
high-risk disease are being preferentially being steered towards transplant, but the proportion 
of ISS stage 3 disease being less in the recent years makes this explanation less likely. The 
proportion of patients progressing within 24 months of the transplant in the latest group is 
consistent with the findings from the phase 3 trial.28, 29 In the CALGB 100104 trial nearly 
50% and 25% of patients in the observation and maintenance lenalidomide arms, 
respectively had relapsed within 24 months consistent with the 36% overall rate of 
progression seen here.29 It is possible that more patients whose disease achieve less than a 
VGPR after AHCT in the earlier years may have gone on to tandem AHCT and thus would 
be excluded from the current study.32 It is also possible this represents underlying biology, 
that is not being significant impacted by the alterations in the short course of induction 
therapy regimen or the post AHCT maintenance, but rather reflect an innate resistance to 
high-dose therapy. This is further underscored by the fact that the induction regimens were 
similar among the patients with a relapse within 24 months and those relapsing after 24 
months. If that is indeed the case, it is important to understand the drivers and possibly 
predict the suboptimal outcomes such that we can design clinical trials for this high-risk 
patient population. The analysis does shed some light into the predictors of early relapse, 
information that could be utilized in designing clinical trials for this patient group.
Consistent with prior data, patients with early relapse continues to represent a poor 
prognosis subgroup of patients, who clearly need a different approach to their management.
9, 12
 In the current study, those relapsing within 24 months of transplant had a significantly 
shorter OS from the time of relapse, compared to those relapsing 24–48 months from AHCT. 
However, it is encouraging to see the improvement in survival of patients from the time of 
relapse in this high-risk group of patients over the years. The improvement is evident 
starting somewhere in the 2004–2008 period, and seems to be maintained over the 
subsequent years (Figure 2D). This improvement in post-relapse survival likely reflects the 
introduction of the newer drugs and more consistent availability of these drugs and the use 
of drug combinations in the setting of relapsed disease. However, the lack of further 
improvement between the 2005–08 cohort and the most recent group highlights the need for 
continued development of novel strategies. It is likely the effect of more recent 
improvements seen with newer drugs such as carfilzomib (FDA-approved in mid-2012), 
pomalidomide (FDA-approved in early 2013), ixazomib and monoclonal antibodies (FDA-
approved later 2015) is likely not reflected here as our dataset covers practice in 2000–2013. 
In addition to the timing of relapse, several other risk factors for poor outcome following 
post AHCT relapse have been identified in the multivariate analysis. These include 
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previously described factors such as the older age and poorer performance status, ISS stage 
III at diagnosis, IgA myeloma and >1 line of therapy prior to AHCT as well as lack of 
maintenance therapy following AHCT. It is certainly of interest that the post-relapse survival 
is higher among those who relapse on maintenance, suggesting lack of development of a 
more resistant disease phenotype among maintained patients and the availability of new 
classes of drugs in the recent years. This finding is consistent with what was seen in a recent 
meta-analysis of trials using post AHCT maintenance.33
The major limitation of our study is the lack of cytogenetic data on patients. Because the 
CIBMTR only collected cytogenetic data after 2008, it is not possible to obtain this 
information. Further, even in the 2008–2013 cohort, there may be heterogeneous FISH 
methodology, variable plasma cell enrichment, and possibility of false negative results. 
Patients defined as stage 3 include DSS and/or ISS 3 given that the ISS was only developed 
in 2004 and our data includes patients from the pre-ISS era. Lastly, we are unable to 
characterize whether the reported relapses were biochemical, clinical or radiological. 
Nevertheless, this study allows us, using a large database capturing the majority of MM 
AHCT activity in the region, to study systematically early relapsers after AHCT and assess 
changes in outcomes over time.
In conclusion, early relapse after initial therapy, in the context of an upfront transplant in this 
study, continues to be a risk and biology defining feature in myeloma. A relatively high 
constant proportion of patients with early relapse highlights critical aspects of biology that 
are not being addressed by current prognostic factors at diagnosis or current therapies. 
Identification of risk factors and well-designed laboratory studies of the tumor and 
microenvironment in these patients will lead to further improvements over time. The 
improved outcomes from relapse is encouraging and this is likely to improve over time with 
introduction of newer therapies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Panel A: Progression free survival from AHCT for the three groups of patients by the date 
of AHCT (2001-204, 2005–2008, 2009–2013).
Panel B: Overall survival from AHCT for the three groups of patients by the date of AHCT 
(2001-204, 2005–2008, 2009–2013)
Panel C: Trends in the proportion of patients with early relapse
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Figure 2. 
Panel A: Overall survival from diagnosis among patients with early relapse (< 24 months) 
and late relapse (>24 months)
Panel B: Post-relapse survival for early relapse patients (relapse within 24 months) 
compared to those with a late relapse
Panel C: Post-relapse survival for early relapse patients who relapsed within 24 months 
grouped by relapse year 2005
Panel D: Post-relapse survival for early relapse patients who relapsed within 24 months, 
grouped by the date of AHCT (2001-204, 2005–2008, 2009–2013)
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Table 1
Patient characteristics at diagnosis
Variable 2001–2004 2005–2008 2009–2013
Number of patients 896 1401 959
Number of centers 102 99 99
Age at transplant, years
 median age (range) 59 (22–80) 59 (23–80) 59 (28–78)
Gender
 Male 536 (60) 841 (60) 558 (58)
Region
 US 761 (85) 1319 (94) 950 (99)
 Canada 135 (15) 82 (6) 9 (<1)
Karnofsky Score
 ≥ 90% 533 (59) 736 (53) 519 (54)
 < 90% 316 (35) 501 (36) 390 (41)
 Unknown 47 (5) 164 (12) 50 (5)
Disease-related variables
Immunochemical subtype
 IgG 517 (58) 762 (54) 551 (57)
 IgA 190 (21) 313 (22) 196 (20)
 Light chain 147 (16) 267 (19) 183 (19)
 Others 9 (1) 17 (1) 15 (2)
 Non-secretory 28 (3) 40 (3) 14 (1)
 Unknown Type 5 (<1) 2 (<1) 0
Serum creatinine at diagnosis
 < 2 mg/dl 595 (66) 930 (66) 664 (69)
 ≥ 2 mg/dl 135 (15) 235 (17) 147 (15)
 Unknown 166 (19) 236 (17) 148 (15)
Serum albumin at diagnosis
 < 3.5 g/dl 274 (31) 416 (30) 313 (33)
 ≥ 3.5 g/dl 388 (43) 676 (48) 486 (51)
 Unknown 234 (26) 309 (22) 160 (17)
ISS/DSS Stage III
 Yes 389 (43) 538 (38) 292 (30)
 No 487 (54) 803 (57) 588 (61)
 Missing 20 (2) 60 (4) 79 (8)
Transplant-related variables
Lines of chemotherapy
 1 606 (68) 956 (68) 779 (81)
 2 236 (26) 358 (26) 140 (15)
 3+ 54 (6) 87 (6) 40 (4)
Chemotherapy
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Variable 2001–2004 2005–2008 2009–2013
 VTD 9 (1) 189 (13) 62 (6)
 RVD 0 79 (6) 467 (49)
 CVD 3 (<1) 117 (8) 134 (14)
 VD 3 (<1) 86 (6) 145 (15)
 RD 2 (<1) 216 (15) 124 (13)
 TD 184 (21) 485 (35) 15 (2)
 VAD/similar 695 (78) 229 (16) 12 (1)
Melphalan dose (mg/m2) for condition regimen
 140 167 (19) 230 (16) 100 (10)
 200 729 (81) 1171 (84) 859 (90)
Total No. of CD34 cells infused (×106/kg)
 Median (range) 6 (1–20) 5 (1–20) 4 (2–19)
Disease status at transplant
 CR 139 (16) 177 (13) 168 (18)
 VGPR† (NA) (NA) 330 (34)
 PR 635 (71) 1069 (76) 408 (43)
 MR/NR/SD 98 (11) 113 (8) 36 (4)
 Relapse/Progression 21 (2) 42 (3) 17 (2)
 Unknown 3 (<1) 0 0
Sensitivity to chemotherapy
 Sensitive 774 (86) 1246 (89) 906 (94)
 Resistant 119 (13) 155 (11) 53 (6)
 Unknown 3 (<1) 0 0
Time from diagnosis to transplant
 < 6 months 284 (32) 391 (28) 399 (42)
 6 – 12 months 612 (68) 1010 (72) 560 (58)
Median follow-up of survivors (range), months 120 (3–170) 86 (3–129) 39 (3–82)
Legend: ISS, International Staging System; DSS, Durie Salmon Stage, VTD, boretezomib, thalidomide and dexamethasone; RVD, lenalidomide, 
bortezomib and dexamethasone; CVD, cyclophosphamide, bortezomib and dexamethasone; VD, bortezomib, dexamethasone; RD, lenalidomide, 
dexamethasone; TD, thalidomide, dexamethasone; VAD, vincristine, doxorubicin, and dexamethasone; CR, complete response; VGPR, very good 
partial response; PR, partial response; MR, minor response; NR, no response; SD, stable disease.
†
This was included only after 2008. Prior to 2008, VGPR patients would be included in PR group
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Table 2
Post-transplant characteristics
Variable 2001–2004 2005–2008 2009–2013
Post-relapse salvage transplant
 No salvage transplant 702 (78) 1097 (78) 890 (93)
 Salvage Auto transplant 165 (18) 254 (18) 58 (6)
 Salvage Allo transplant 29 (3) 50 (4) 11 (1)
Time from transplant to relapse
 NRM 74 (8) 83 (6) 23 (2)
 < 12 months 155 (17) 280 (20) 444 (46)
 12 – 24 months 201 (22) 265 (19) 198 (21)
 24 – 36 months 141 (16) 270 (19) 138 (14)
 36 – 48 months 94 (10) 218 (16) 80 (8)
 >= 48 months 62 (7) 133 (9) 41 (4)
 No relapse and alive 169 (19) 152 (11) 35 (4)
Planned post-HCT therapy
 Novel agents (Lena+Bort/Lena/Bort)‡ 30 (3) 267 (19) 695 (72)
 Other agents 29 (3) 54 (4) 6 (<1)
 None 818 (91) 1010 (72) 236 (25)
 Missing 19 (2) 70 (5) 22 (2)
Legend NRM: non-relapse mortality
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Table 3
Characteristics of patients grouped by timing of relapse*
Variable Relapse <24 months Relapse after 24 months No Relapse
Number of patients 1156 984 893
Age at transplant, years
 median age (range) 58 (31–80) 60 (28–78) 59 (22–80)
 <50 216 (19) 171 (18) 167 (19)
 50–69 857 (75) 747 (76) 676 (76)
 70+ 83 (7) 66 (7) 50 (6)
Gender
 Male 697 (60) 596 (61) 512 (57)
Karnofsky Performance Score
 ≥ 90% 623 (54) 535 (54) 506 (57)
 < 90% 436 (38) 369 (38) 331 (37)
 Unknown 97 (8) 80 (8) 56 (6)
Disease-related variables
Immunochemical subtype
 IgG 619 (54) 565 (57) 519 (58)
 IgA 300 (26) 209 (21) 152 (17)
 Light chain 186 (16) 169 (17) 191 (21)
 Others 17 (1) 12 (1) 9 (1)
 Non-secretory 31 (3) 27 (3) 20 (2)
Serum Creatinine at diagnosis
 < 2 mg/dl 787 (68) 666 (68) 597 (67)
 ≥ 2 mg/dl 196 (17) 152 (15) 131 (15)
 Unknown 173 (15) 166 (17) 165 (18)
Serum Albumin at diagnosis
 < 3.5 g/dl 384 (33) 306 (31) 254 (28)
 ≥ 3.5 g/dl 515 (45) 473 (48) 448 (50)
 Unknown 257 (22) 205 (21) 191 (21)
ISS/DS Stage III
 Yes 474 (41) 367 (37) 300 (34)
 No 629 (54) 580 (59) 554 (62)
 Missing 53 (5) 37 (4) 39 (4)
Transplant-related variables
Lines of chemotherapy
 1 783 (68) 701 (71) 683 (76)
 2 302 (26) 223 (23) 167 (19)
 3+ 71 (6) 60 (6) 43 (5)
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Variable Relapse <24 months Relapse after 24 months No Relapse
Chemotherapy
 VTD 98 (8) 93 (9) 64 (7)
 RVD 181 (16) 94 (10) 211 (24)
 CVD 80 (7) 63 (6) 72 (8)
 VD 76 (7) 55 (6) 79 (9)
 RD 134 (12) 88 (9) 103 (12)
 TD 234 (20) 276 (28) 152 (17)
 VAD/similar 353 (31) 315 (32) 212 (24)
Melphalan dose (mg/m2) for condition regimen
 140 198 (17) 146 (15) 128 (14)
 200 958 (83) 838 (85) 765 (86)
Total No. of CD34 cells infused (×106/kg)
 Median (range) 4.81 (1.00–19.11) 5.34 (1.18–19.70) 5.08 (1.19–19.56)
Disease status at transplant
 CR 142 (12) 140 (14) 171 (19)
 PR 860 (74) 760 (77) 652 (73)
 MR/NR/SD 108 (9) 67 (7) 56 (6)
 Relapse/Progression 45 (4) 16 (2) 14 (2)
 Unknown 1 (<1) 1 (<1) 0
Sensitivity to chemotherapy
 Sensitive 1002 (87) 900 (91) 823 (92)
 Resistant 153 (13) 83 (8) 70 (8)
 Unknown 1 (<1) 1 (<1) 0
Time from diagnosis to transplant
 < 6 months 368 (32) 325 (33) 301 (34)
 6 – 12 months 788 (68) 659 (67) 592 (66)
Year of transplant
 2001–2004 331 (29) 325 (33) 198 (22)
 2005–2008 520 (45) 503 (51) 323 (36)
 2009–2013 305 (26) 156 (16) 372 (42)
Median follow-up of survivors (range), months 75 (24–169) 97 (25–170) 60 (24–170)
Post-transplant characteristics
Post-relapse salvage transplant
 No salvage transplant 938 (81) 699 (71) 893
 Salvage AutoHCT 159 (14) 267 (27) 0
 Salvage AlloHCT 59 (5) 18 (2) 0
Time from transplant to relapse
 < 12 months 624 (54) 0
 12 – 24 months 532 (46) 0
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Variable Relapse <24 months Relapse after 24 months No Relapse
 24 – 36 months 0 392 (40)
 > 36 months 0 236 (24)
Planned post-HCT therapy
 Novel agents (Lena+Bort/Lena/Bort) 272 (24) 254 (26) 370 (41)
 Other agents 20 (2) 39 (4) 28 (3)
 None 813 (70) 644 (65) 485 (54)
 Missing 51 (4) 47 (5) 10 (1)
*
Limited to patients with at least 24 months follow up if still alive
Legend VTD, boretezomib, thalidomide and dexamethasone; RVD, lenalidomide, bortezomib and dexamethasone; CVD, cyclophosphamide, 
bortezomib and dexamethasone; VD, bortezomib, dexamethasone; RD, lenalidomide, dexamethasone; TD, thalidomide, dexamethasone; VAD, 
vincristine, doxorubicin, and dexamethasone; CR, complete response; VGPR, very good partial response; PR, partial response; MR, minor 
response; NR, no response; SD, stable disease; HCT hematopoietic cell transplantation
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Table 6
Multivariate analysis of post-relapse survival
Variable Number Hazard Ratio 95% Confidence Interval p-value
Relapse Group <0.0001
-Late relapse 628 1
-Early relapse 1213 1.43 1.26, 1.62
Age at AHCT 0.06
-18–49 334 1
-50–59 648 1.15 0.97, 1.37 0.10
-60–69 727 1.23 1.04, 1.46 0.02
-70+ 132 1.33 1.03, 1.71 0.03
Stage III at Diagnosis <0.0001
-No 1010 1
-Yes 747 1.28 1.13, 1.45 <0.0001
-Missing 84 1.01 0.73, 1.40 0.89
Immunochemical subtype 0.0006
-IgG 1010 1
-IgA 441 1.30 1.13, 1.49 0.0002
-Light chain 309 0.90 0.76, 1.06 0.20
-Non-secretory/others 73 1.00 0.74, 1.35 1.00
-Missing 4 0.83 0.27, 2.61 0.75
Karnofsky Performance Score at AHCT 0.007
-≥90% 995 1
-<90% 686 1.21 1.07, 1.36 0.003
-Missing 160 1.07 0.86, 1.34 0.82
Lines of Pre-AHCT chemotherapy 0.005
-1 1273 1
-2+ 568 1.20 1.10, 1.35
Post-transplant maintenance <0.0001
-No/Other agents 1286 1
-Novel agents 473 0.73 0.63, 0.85 <0.0001
-Missing 82 0.60 0.45, 0.80 0.0006
Legend AHCT, autologous hematopoietic cell transplantation
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